









COMPOSITIONS OR COMBINED PREPARATIONS OF ESSENTIAL OILS AND L-CARNITINE

A research group from CIBER, the Biomedical Research Institute of Malaga and Nanomedicine Platform (IBIMA Plataforma Bionand), Andalusian Health Service (SAS) and the University of Malaga (UMA) has developed a composition of essential oils and L-Carnitine against cardiometabolic diseases.

The Need

Ischaemic heart disease (IHD) and type 2 diabetes mellitus (T2DM) are currently two problematic health conditions worldwide that are closely related due to the association between metabolic status and cardiovascular risk. Previous studies in both diseases suggest a link between gut microbiota and these pathologies.

The consumption of the Mediterranean diet has antiinflammatory and antioxidant properties. In addition, it has been linked to an increase in beneficial bacteria, such as those involved in the production of healthimportant short-chain fatty acids. However, these beneficial effects have been found to be limited.

The Solution

For this reason, a research group has developed a composition of essential oils from plants found in the Mediterranean diet together with L-carnitine. One example of the effect of these nutraceutical formulas on the microbiota is the reduction of pro-atherogenic substances of bacterial origin, such as TMAO, which are associated with the development of cardiovascular diseases.

In addition to the beneficial effects of the Mediterranean diet, these essential oil-based formulas have specific effects on cardiometabolic diseases such as IHD and T2DM.

Innovative Aspects

- Enables prebiotic enhancement of gut microbiota in relation to IC and T2DM.
- Has beneficial effects on IC and T2DM due to its anti-inflammatory and antioxidant activity.

Stage of Development:

Validated in a gnotobiotic murine model carrying colonic microbiota derived from patients with IHD and T2DM.

Intellectual Property:

- Priority European patent application filed (October 14, 2022)
- Suitable for international extension (PCT application)

Aims

Looking for a partner interested in a license and/or a collaboration agreement to develop and exploit this asset.



Contact details

Consorcio Centro de Investigación Biomédica en Red (CIBER) otc@ciberisciii.es https://www.ciberisciii.es/en